Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Apoptosis*/drug effects ; Apoptosis*/immunology; Glioblastoma/*immunology ; Immunity, Cellular/*drug effects ; Killer Cells, Natural/*immunology ; Temozolomide/*pharmacology; Coculture Techniques ; Glioblastoma/pathology ; Glioblastoma/therapy ; Humans ; K562 Cells ; Killer Cells, Natural/pathology

Glioblastoma is the leading malignant glioma with a poor prognosis. This study aimed to investigate the antitumor effects of natural killer cells in combination with temozolomide as the standard chemotherapeutic agent for glioblastoma. Using a simple, feeder-less, and chemically defined culture method, we expanded human peripheral blood mononuclear cells and assessed the receptor expression, natural killer cell activity, and regulatory T cell frequency in expanded cells. Next, using the standard human glioblastoma cell lines (temozolomide-sensitive U87MG, temozolomide-resistant T98G, and LN-18), we assessed the ligand expressions of receptors on natural killer cells. Furthermore, the antitumor effects of the combination of the expanded natural killer cells and temozolomide were assessed using growth inhibition assays, apoptosis detection assays, and senescence-associated β-galactosidase activity assays in the glioblastoma cell lines. Novel culture systems were sufficient to attain highly purified (>98%), expanded (>440-fold) CD3-/CD56+ peripheral blood-derived natural killer cells. We designated the expanded population as genuine induced natural killer cells. Genuine induced natural killer cells exhibited a high natural killer activity and low regulatory T cell frequency compared with lymphokine-activated killer cells. Growth inhibition assays revealed that genuine induced natural killer cells inhibited the glioblastoma cell line growth but enhanced temozolomide-induced inhibition effects in U87MG. Apoptosis detection assays revealed that genuine induced natural killer cells induced apoptosis in the glioblastoma cell lines. Furthermore, senescence-associated β-galactosidase activity assays revealed that temozolomide induced senescence in U87MG. Genuine induced natural killer cells induce apoptosis in temozolomide-sensitive and temozolomide-resistant glioblastoma cells and enhances temozolomide-induced antitumor effects in different mechanisms. Hence, the combination of genuine induced natural killer cells and temozolomide may prove to be a promising immunochemotherapeutic approach in patients with glioblastoma if the antitumor effects in vivo can be demonstrated.
Competing Interests: We have the following interests. Tsutomu Nakazawa and Hiromichi Morita are affiliated to Grandsoul Research Institute for Immunology, Inc. and Takahiro Tsujimura to Clinic Grandsoul Nara. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Front Immunol. 2018 Jan 05;8:1825. (PMID: 29354116)
Front Immunol. 2017 Sep 13;8:1124. (PMID: 28955340)
J Neurooncol. 1990 Oct;9(2):125-30. (PMID: 2175768)
Nat Immunol. 2016 Aug 19;17(9):1025-36. (PMID: 27540992)
Sci Rep. 2017 Sep 11;7(1):11075. (PMID: 28894091)
J Neurooncol. 2014 Jan;116(1):1-9. (PMID: 24085644)
Clin Cancer Res. 2018 Apr 15;24(8):1834-1844. (PMID: 29444931)
Exp Ther Med. 2017 Jul;14(1):831-840. (PMID: 28673007)
Science. 2004 Nov 26;306(5701):1517-9. (PMID: 15567854)
Adv Exp Med Biol. 2012;746:109-20. (PMID: 22639163)
J Transl Med. 2015 Aug 25;13:277. (PMID: 26303618)
Cytotherapy. 2015 May;17(5):621-32. (PMID: 25881519)
Cytotherapy. 2016 Nov;18(11):1410-1421. (PMID: 27421740)
J Neuroimmunol. 2013 Nov 15;264(1-2):71-83. (PMID: 24045166)
J Immunol. 1998 Jul 15;161(2):571-7. (PMID: 9670929)
Nature. 1998 Feb 19;391(6669):795-9. (PMID: 9486650)
FASEB J. 2014 Jul;28(7):2932-41. (PMID: 24736413)
Blood. 2013 Apr 4;121(14):2659-68. (PMID: 23377437)
Chin J Cancer Res. 2018 Apr;30(2):173-196. (PMID: 29861604)
Immunol Rev. 2006 Dec;214:229-38. (PMID: 17100888)
Immunol Rev. 2010 May;235(1):267-85. (PMID: 20536569)
Blood. 2008 Aug 1;112(3):461-9. (PMID: 18650461)
Lancet Oncol. 2009 May;10(5):459-66. (PMID: 19269895)
Annu Rev Immunol. 2005;23:225-74. (PMID: 15771571)
J Immunol. 2014 Jul 15;193(2):519-28. (PMID: 24928990)
Anticancer Res. 2004 May-Jun;24(3b):1861-71. (PMID: 15274367)
Eur J Immunol. 2014 Jun;44(6):1582-92. (PMID: 24777896)
Apoptosis. 2002 Feb;7(1):41-7. (PMID: 11773704)
Trends Immunol. 2001 Nov;22(11):633-40. (PMID: 11698225)
J Immunol Methods. 1994 Jun 24;172(2):227-39. (PMID: 7518485)
J Immunother. 2009 Nov-Dec;32(9):914-9. (PMID: 19816190)
Front Oncol. 2013 Nov 11;3:275. (PMID: 24273748)
Klin Padiatr. 2005 Nov-Dec;217(6):345-50. (PMID: 16307421)
Cell Mol Immunol. 2013 May;10(3):230-52. (PMID: 23604045)
J Neurosurg. 2011 Sep;115(3):505-11. (PMID: 21663411)
J Neurooncol. 2016 Sep;129(2):231-41. (PMID: 27393349)
Nat Immunol. 2008 May;9(5):503-10. (PMID: 18425107)
Nat Rev Cancer. 2016 Jan;16(1):7-19. (PMID: 26694935)
Cell. 1995 Sep 8;82(5):697-700. (PMID: 7671299)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Anticancer Res. 2013 Jun;33(6):2525-33. (PMID: 23749904)

YF1K15M17Y (Temozolomide)

Date Created: 20190307 Date Completed: 20191125 Latest Revision: 20200309

20231215

PMC6402639

10.1371/journal.pone.0212455

30840664